#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Sarcoma Pulmonary sarcoidosis Nasopharyngeal cancer Infantile spasms Cholangitis sclerosing Ewing's sarcoma Cutaneous calcification Cutaneous T-cell lymphoma Chronic graft versus host disease in intestine Renal disorder Prodromal Alzheimer's disease Oesophageal adenocarcinoma stage II Marfan's syndrome Pemphigus Alveolar proteinosis More trials…

    Learn about Rare Diseases

    Progressive supranuclear palsy – Basic Information Mast cell activation syndrome – Basic Information Cholangitis sclerosing Malignant fibrous histiocytoma – Basic Information Lymphatic malformation Glomerulonephritis membranoproliferative – Life with Disease Ehlers-Danlos syndrome – Diagnostics IgA nephropathy – Treatment Amyotrophic lateral sclerosis Leiomyosarcoma recurrent – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dsimc Insulin Glargine Ixekizumab Glepaglutide POTASSIUM HYDROXIDE Clic-1901 Cart REGN7999 Cefuroxime Sodium Erlotinib ACARBOSE Latanoprost AZD6234 Paracetamol Ph. Eur. Dexamethasone Sodium Phosphate Tacrolimus NALOXEGOL Reparixin Hepatitis B Surface Antigen DROSPIRENONE Eplontersen More therapies…

    Learn about Your Condition

    Arteriovenous graft thrombosis BRAF gene mutation Medulloblastoma recurrent Cytomegalovirus infection Endometrial cancer stage III Necrotising myositis Cardiomyopathy Tachypnoea Anal incontinence Leiomyosarcoma Mitral valve incompetence Oxygen saturation Hepatic cancer Toxic epidermal necrolysis Sjogren's syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Migraine

  • Study on the Safety and Tolerability of Lasmiditan for Treating Migraine in Children Aged 6 to 17

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Lasmiditan
    Belgium France Germany Italy The Netherlands Romania +1

  • Study on Galcanezumab for Preventing Chronic Migraine in Adolescents Aged 12 to 17

    Not recruiting

    3 1
    Investigated Drugs:
    • Galcanezumab
    Denmark France Italy The Netherlands Spain

  • Study on Galcanezumab for Preventing Episodic Migraine in Children and Teens Aged 6 to 17

    Not recruiting

    3 1
    Investigated Drugs:
    • Galcanezumab
    Denmark Italy The Netherlands Spain

  • Study on Botulinum Toxin Type A for Preventing Chronic Migraine in Adults

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Botulinum Toxin Type A – Haemagglutinin Complex
    Czechia Germany Italy Poland Spain

  • Study on Botulinum Toxin Type A for Preventing Episodic Migraine in Adults

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Botulinum Toxin Type A – Haemagglutinin Complex
    Czechia France Germany Poland Spain

  • Study on Long-Term Safety of Atogepant for Preventing Migraine in Patients with Chronic or Episodic Migraine

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Migraine with aura
    • Migraine without aura
    • Migraine
    Investigated Drugs:
    • Atogepant
    Czechia Denmark France Germany Hungary Italy +3
Previous Page
1 … 6 7 8

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!